OBJECTIVE: To describe the outcomes of pregnancies exposed to IL-1 targeted therapies (anti-IL-1): anakinra and/or canakinumab. METHODS: We performed a descriptive observational study based on data from CRAT, the French Teratology Information Service. We included prospective and retrospective pregnancies exposed to anakinra and/or canakinumab with known outcomes. Pregnancy, foetal and neonatal outcomes were analysed. RESULTS: Between 2007 and 2023, 57 pregnant women exposed to anti-IL-1 were referred, including 27 (47.3%) treated for Still's disease. Among prospective cases, 52 foetuses (one twin pregnancy) were exposed to anakinra (n = 43), canakinumab (n = 5) or both medications (n = 4). For anakinra: (i) 40/47 cases (85.1%) were exposed during the first trimester (T1), and 21/47 (44.7%) during all pregnancy, (ii) 40/47 (85.1%) resulted in livebirths, 5/47 (10.6%) early miscarriages, one medical abortion (mother-transmitted syndrome) and one elective abortion, (iii) one isolated hypospadias was reported (anakinra between 0 and 4 weeks of gestation), for a prevalence of major congenital malformation of 3.03% IC 95% [0.1-15.1] among T1-exposed pregnancies. For canakinumab, all cases (9/9) were exposed during T1 and 2/9 during all pregnancy: all resulted in livebirths with no malformation. Concerning retrospective pregnancies (anakinra = 6/6), all resulted in live births. Cardiopathy with hypospadias was identified in a child with a rare genetic anomaly. No significant effects were reported while breastfeeding (n = 9). CONCLUSION: In this study, the largest series to date, our results do not suggest occurrence of specific negative outcomes in pregnancies exposed to anti-IL-1. The imputability of anakinra in the malformations observed is unlikely. If needed, their use during pregnancy should be considered.
No takes yet. Share an insight, caveat, or question.
Faure‐Bardon et al. (2025) studied this question.